Volitionrx (VNRX) Liabilities and Shareholders Equity (2011 - 2026)

Volitionrx (VNRX) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $6.9 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 26.58% year-over-year to $6.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $30.6 million (down 43.98% YoY) and the FY2025 annual result came in at $6.9 million, down 26.58% from the prior year.
• Liabilities and Shareholders Equity improved to $6.9 million in Q4 2025, from $6.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $35.2 million in Q2 2021 to a low of $6.4 million in Q3 2025.
• A 5-year average of $19.3 million and a median of $18.3 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity surged 52.78% — and 2024, when it slumped 66.37%.
• Tracing VNRX's Liabilities and Shareholders Equity over 5 years: stood at $27.5 million in 2021, then slumped by 33.45% to $18.3 million in 2022, then surged by 52.78% to $28.0 million in 2023, then plunged by 66.37% to $9.4 million in 2024, then dropped by 26.58% to $6.9 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $6.9 million (Q4 2025), $6.4 million (Q3 2025), and $8.7 million (Q2 2025), per Business Quant data.